J&J Risperdal "Dear Doctor" Letter Minimizes Diabetes Risk, FDA Ad Division Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency warning letter says J&J inappropriately claimed that Risperdal is safer than other atypical antipsychotics. The company is working with FDA to address the agency's concerns as quickly as possible.
You may also be interested in...
J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award
A jury finds that J&J misrepresented the safety profile of Risperdal in a verdict for the state of Louisiana; each letter and sales rep call was counted as a separate violation.
J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award
A jury finds that J&J misrepresented the safety profile of Risperdal in a verdict for the state of Louisiana; each letter and sales rep call was counted as a separate violation.
Janssen Corrects Risperdal "Dear Doctor" Letter
The action follows an FDA warning letter in April. Janssen's previous letter to doctors had suggested Risperdal was safer than other atypical antipsychotics.